Loading...
OTCM
ATTOF
Market cap4kUSD
Aug 18, Last price  
0.00USD
1D
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Atento SA

Chart & performance

D1W1MN
OTCM:ATTOF chart
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
23.96%
Rev. gr., 5y
-76.59%
Revenues
1m
-99.91%
2,290,500,0002,341,115,0002,298,324,0001,965,600,0001,757,498,0001,921,300,0001,818,200,0001,707,300,0001,412,300,0001,449,200,0001,350,000
Net income
-61m
L-32.79%
-679,440,000-4,039,000-42,152,00049,148,00065,000-16,800,00018,500,000-80,700,000-46,800,000-90,200,000-60,627,000
CFO
-59m
L
99,599,000135,295,00036,978,000141,946,000114,452,00081,200,00046,400,000128,200,00042,300,000-59,199,000
Dividend
Nov 09, 20170.3384 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
URL
https://www.atento.com
IPO date
Oct 02, 2014
Employees
135,000
Domiciled in
LU
Incorporated in
LU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT